EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul
Executive Summary
The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.
You may also be interested in...
EU Prepares To Release Major Pharma Legislative Overhaul
The much heralded – and oft delayed – revision of the EU pharmaceutical legislative framework is about to be published. R&D-based pharma firms as well as generic and biosimilar companies will be keeping a close eye on proposals such as reductions in regulatory data protection and market exclusivity periods.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.
EU Data Protection Reductions Would ‘Irretrievably Sabotage’ Pharma Industry
With the proposals for an overhaul of the EU pharmaceutical legislation tentatively scheduled for publication on 29 March, the European industry federation EFPIA claims that the plans as currently drafted will drive investment away and damage the industry’s ability to compete at global scale. But the European Commission insists the revision will boost industry's global competitiveness and innovative power.